Hints and tips:
Related Special Reports
...Eli Lilly chief executive David Ricks described the acquisition as “unusual” on Tuesday and called for competition authorities to look into the deal....
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...One banker following the sector said Zealand’s amylin treatment was “one of the most advanced” in development and would make it an attractive acquisition target....
...New Mountain bought a controlling stake in Citrin Cooperman in 2022 and has helped fund an acquisition spree that has swelled the accounting firm’s annual revenues to an estimated $700mn....
...its own Toyota shares it would reacquire as a result of the acquisition”....
...Actis is General Atlantic’s largest acquisition, pushing the New York-based investment group to nearly $100bn in total assets....
...The acquisition also gives Novo Nordisk more expertise in RNA-based therapies, a growing field in pharmaceuticals....
...Novo Holdings owns 28 per cent of the shares in Novo Nordisk but has 77 per cent of the voting rights....
...Prior to the acquisitions last month, Novo Nordisk CEO Lars Fruergaard Jørgensen warned: “there’ll be a demand that outgrows what can be produced by us, and probably also competition”....
...Novo Nordisk said that the deal and its consequent acquisition of the sites would be subject to regulatory and shareholder approval....
...According to Dealogic, the outlay by Novo Nordisk and Eli Lilly compares to a total of $305mn that the entire pharmaceutical industry spent on acquisitions and partnerships in the field in the previous ten...
...Kutay and Novo Nordisk’s leadership “looked at each other and said ‘hold on a second’”, he said. Last week, Kutay led a $16.5bn acquisition of Catalent....
...Some of the biggest deals struck in the quarter included Capital One’s $35bn acquisition of Discover Financial, and chip design toolmaker Synopsys’s $35bn takeover of engineering software maker Ansys....
...Novo bulks up to boost sales of weight-loss drugs The Danish pharma giant Novo Nordisk has become Europe’s most valuable corporation by making drugs that help people lose weight....
For regulators, the labour market is fair game in mergers and acquisitions
...Need to know: business Novo Nordisk announced a €1bn deal for a German biotech developing therapies to treat heart disease, as the Danish group seeks to branch out from its blockbuster diabetes and weight...
Plus, the life of a Rothschild and the leveraged finance world sweats it out at JPMorgan’s confab in Miami
...This month Novo Nordisk signed deals worth up to $1bn with US biotechs, following several acquisitions last year....
The partnership between US activist Jana and Cannae might not have to look far for potential targets
...In November, the drugmaker announced a licensing agreement with Shanghai-based Eccogene for a potential obesity pill, which belongs to the same category as Novo Nordisk’s Wegovy weight loss treatment....
...A senior EU court adviser has said the European Commission was wrong to block gene sequencing group Illumina’s $8bn acquisition of Grail and that the decision should be scrapped....
Culture secretary ‘minded to refer’ deal involving British media group to Competition and Markets Authority
Nasdaq-listed Viavi has turned to Silver Lake for investment to back its £1bn deal to buy Spirent
...Buyout groups are betting they can grow these businesses through acquisitions and turn many into companies large enough to eventually be listed on public markets....
...The Federal Trade Commission has sued to block Kroger’s acquisition of Albertsons, threatening the largest supermarket merger in US history in the latest sign of Washington’s crackdown on anti-competitive...
International Edition